GSK ends restless leg syndrome collaboration

Hannah Blake


GSK and XenoPort have announced mutual termination of their collaboration concerning restless leg syndrome drug, Horizant, for which GSK had commercialisation rights and certain development rights in the United States.

Under the termination agreement, GSK will return Horizant (gabapentin enacarbil) rights to XenoPort and will provide assistance during the transition period ending 30th April 2013, upon mutually agreed terms. During this period, GSK will continue to exclusively commercialise, promote, manufacture and distribute Horizant Extended-Release Tablets.

The two companies have been in a legal battle over the drug since January, when XenoPort alleged GSK breached a contractual obligation. The mutual termination resolves all litigation between the two companies.

GSK has stated that the decision was based on the company’s ongoing strategy to streamline its portfolio and only focus on core franchise opportunities.




Related news:

GlaxoSmithKline, XenoPort End Horizant Collaboration Pact (FOX Business)

XenoPort, Glaxo end collaboration on restless legs syndrome drug (Reuters)

Reference links:

GSK press release

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.